On a roll, Re­gen­eron and Sanofi boast pos­i­tive PhI­II OS re­sults in 'no­to­ri­ous­ly' tough can­cer

As the sixth check­point in­hibitor on the US mar­ket, Re­gen­eron and Sanofi’s Lib­tayo has claimed quite a few firsts. And they can now add one more feath­er to their PD-1 cap.

The com­pa­nies re­vealed ear­ly Mon­day that they’re stop­ping a Phase III cer­vi­cal can­cer tri­al ear­ly af­ter Lib­tayo was shown to cut the risk of death by 31% over chemother­a­py, paving way for reg­u­la­to­ry sub­mis­sions lat­er this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.